DOJ Reschedules Marijuana Products: Implications for Medical Research and Procurement

In a significant shift for federal drug policy, the Department of Justice (DOJ) and the Drug Enforcement Administration (DEA) have officially reclassified both FDA-approved marijuana products and marijuana products that are licensed within participating states to Schedule III under the Controlled Substances Act. This reclassification, effective April 2026, aims to bolster both medical research and patient access to these products while maintaining strict federal oversight of their usage and distribution. By facilitating this change, the DOJ seeks to align federal regulations with increasingly supportive state-level policies on the medical use of marijuana, paving the way for expanded therapeutic applications.

This reclassification arrives in the aftermath of policy directives from President Trump aimed at enhancing medical marijuana research. Specifically, the move responds to an executive order issued in December 2025, which prioritized medical marijuana and cannabidiol (CBD) research. The regulatory updates are bolstered by a commitment to ensure that there is consistency in enforcement and regulations across the country. As articulated by Acting Attorney General Todd Blanche, the new regulations are set to allow continued innovation in the area of medical treatment while giving law enforcement the tools necessary to combat illicit drug trafficking effectively.

In conjunction with this move, an expedited administrative hearing process is slated to commence on June 29, 2026. This hearing will delve into potential further adjustments to marijuana’s classification—specifically considering a broader rescheduling from Schedule I to Schedule III. This detail is particularly noteworthy for stakeholders across various sectors, including organizations engaged in medical research, pharmaceutical supply, and healthcare services. By soliciting input from key players, the DOJ hopes to create a legally compliant avenue to evaluate changes in marijuana's status, enhancing regulatory clarity.

The immediate implications of this decision are significant for actors involved in federal procurement and contracting. With evolving regulatory frameworks surrounding marijuana-based treatment options, medical providers and researchers can brace for adjustments in compliance requirements. Healthcare suppliers are likely to see a shift in the types of products eligible for government contracts, as the emphasis on approved Schedule III marijuana products could yield new procurement opportunities. The forthcoming discussions in June will present an invaluable chance for stakeholders to address regulatory concerns and influence the direction of future procurement systems.

The comprehensive reform initiative is designed to enhance access to approved therapies while upholding strict federal controls to mitigate risks associated with substance misuse. DEA Administrator Terry Cole emphasized that these changes aim to inject clarity and consistency into an area previously marred by confusion, thereby supporting law enforcement's ongoing responsibilities to combat issues like the fentanyl epidemic.

In summary, the rescheduling of marijuana products to Schedule III is poised to overhaul existing procurement landscapes through the lens of medical research and regulatory compliance. As stakeholders prepare for this shift, preparation for updated federal guidelines becomes paramount to tapping into new contracting avenues associated with marijuana-based treatments. The anticipated administrative hearing on June 29 will further define the procurement landscape as it relates to the cannabis sector, with the potential for increased access and investment in healthcare treatments historically overshadowed by stringent regulations.

• The DOJ reclassified FDA-approved marijuana products to Schedule III as of April 2026.
• An expedited administrative hearing starts June 29, 2026, to evaluate broader rescheduling of marijuana.
• New opportunities may arise for federally regulated research contracts involving Schedule III substances.
• Healthcare and medical research organizations should prepare for federal guideline updates.
• Senior officials emphasize this action as a commitment to improve patient care and medical research.
• The regulatory changes reflect compliance with international obligations under the Single Convention on Narcotic Drugs.